Compare PASG & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PASG | AEON |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | 27 | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 19.0M |
| IPO Year | 2020 | N/A |
| Metric | PASG | AEON |
|---|---|---|
| Price | $4.70 | $0.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $14.00 | $7.20 |
| AVG Volume (30 Days) | ★ 74.9K | 29.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.51 |
| 52 Week High | $20.00 | $1.45 |
| Indicator | PASG | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 48.45 |
| Support Level | $3.94 | $0.70 |
| Resistance Level | $5.92 | $0.75 |
| Average True Range (ATR) | 0.60 | 0.05 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 44.52 | 92.59 |
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.